Na/K/2CI cotransport carrier plays an important role in fluid absorption and secretion in many epithelial tissues. The role of the carrier, however, in mammalian choroidal cerebrospinal fluid (CSF) production has been controversial. We used ventriculo-cisternal perfusion (VCP) labeled with blue dextran with or without bumetanide and measured choroidal CSF production in anesthetized, and paralyzed, mechanically ventilated dogs. During 3 h of VCP, mean intracerebroventricular and arterial pressures, Paco2, pH, IHCO3I, and serum osmolality remained normal in both groups (n = 9 in each group). Beginning 90 min after the start of VCP, choroidal CSF production was measured every 15 min. In group I (control group), values for CSF production (means±SD) were 49±20, 49±21, 51+21, 51±23, 48±20, 56±24, and 48±20 gl/min, at 90, 105, 120, 135, 150, 165, and 180 min, respectively. These values did not differ significantly from each other. In group II (bumetanide group), after baseline control CSF production had been determined at 90 and 105 min. bumetanide (10-' mol/liter) was added to VCP. Mean values for CSF production were 54±15 and 52±17 ,ul/min before, and 39±25, 34±19, 28±10, 30±17, and 30±18,gl/min after addition of bumetanide at 90,105,120, 135, 150, 165, and 180 min, respectively. Comparing the two groups, baseline values for CSF production measured at 90 and 105 min did not differ significantly. After addition of bumetanide (group II), however, decrements in CSF production varied from 30±27% at 120 min to 47±14% at 150 min, which were significantly different from changes in group I. The results of this study indicate that NaCl cotransport carrier is involved in secretion of CSF in dogs, and inhibition of the transporter results in -50% reduction in CSF production. (J. Clin. Invest. 1993. 92:2257-2261
Introduction
In the central nervous system (CNS),' cerebrospinal fluid (CSF) is continuously formed and reabsorbed at a slow rate. The choroid plexus (CP) located in the four cerebral ventricles is thought to be the main site of CSF production (one third of CSF is produced by extrachoroidal tissue; for review, see references [1] [2] [3] [4] [5] . A choroid plexus cell is shown diagrammatically in Figure 1 . These specialized secretory cells are equipped with enzymatic machinery necessary for formation and secretion of CSF.
Chemical analysis of ionic composition of CSF shows that Na + and Cl -are the two ions present in the highest concentrations. Therefore, transport of Na+ and Cl -across CP cells is of primary importance to CSF formation. As depicted in Fig. 1 , the apical (CSF) side ofthe CP cell membrane contains the Na, K-ATPase pump (6) , which results in active secretion of Na+ into CSF. Appropriate amounts ofCl-and HCO-follow secretion of Na+ into CSF to satisfy electroneutrality, and H20 to satisfy isotonicity.
Continuous secretion of Na+ and Cl-into CSF across the apical membrane of the CP cells requires continuous inward flux of the ions across the basolateral membrane (plasma side) (Fig. 1 ). There are several mechanisms which may mediate the transport of Na+ and Cl-into CP cells across the basolateral membrane including the carrier which cotransports NaCl (Fig. 1 ).
Although NaCl cotransport carrier has not been isolated, its function has been well studied outside the CNS (7, 8) , and it is known that the carrier plays a major role in NaCl cotransport and H20 absorption in the ascending loop of Henle in the mammalian nephron. The loop diuretics, e.g., furosemide and bumetanide, combine with the carrier at the Cl-site (9, 10) and consequently inhibit salt transport by the carrier.
The role ofNaCl cotransport in mammalian CSF secretion, however, has been controversial (for review see reference 5). Investigators have used loop diuretics and measured CSF production (by various methods) to study the function of the carrier in the CNS (11) (12) (13) (14) (15) (16) (17) (18) . The interpretation of the results of these studies is subject to controversy because of the methodological reasons detailed elsewhere (5) . Briefly, these include (a) the renal effect of the diuretics when given systemically resulting in volume depletion, (b) the carbonic anhydrase (CA) inhibitory activity of furosemide within CNS (a and b, per se, may decrease CSF production), (c) lack of measurements of serum and CSF concentrations of furosemide or bumetanide and their CA inhibitory activity, (d) lack of appropriate control, since with time CSF production usually decreases, and (e) lack of careful control of hemodynamics, ventilation, arterial blood acid-base balance, and electrolytes, which can affect CSF production.
With these considerations, the present study was designed to directly measure CSF production under carefully controlled standardized conditions in dogs. The results show that NaCl cotransport carrier mediates CSF production in this mammalian species, and inhibition of the carrier results in -50% reduction in production rate. 
Results
The mean arterial, left and right cerebroventricular pressures, arterial Pco2, pH, [HCO-I (Table I) , electrolytes, and hematocrit (Table II) did not differ significantly with time or when the two groups were compared. In group I cisternal CSF production remained stable and did not change significantly during the period of observation.
Values for CSF production were 49±20, 49±21, 51±+21, 51±23, 48±20, 56±24and48±20 Al/min, at 90, 105, 120, 135, 150, 165, and 180 min, respectively, after beginning of VCP. Respective values for group II were 54±15 and 52±17 before and 39±25, 34±19, 28±10, 30±17, and 30±18 Al/min after addition of bumetanide to infusate. In group II, after addition of bumetanide, CSF production progressively decreased, with maximum inhibition occurring at 150 min (P = 0.003), about 45 min after infusion with bumetanide.
Comparing the two groups, values of baseline CSF production at 90 and 105 min (i.e., before addition of bumetanide in group II) were similar and did not differ significantly (see above). However, afterwards, the mean values were consistently lower in bumetanide treated dogs than in control animals and statistical significance was achieved at 150 and 165 min (P = 0.02). Fig. 2 shows percent change in CSF production from baseline; the latter was calculated for each group, as the mean of all values at 90 and 105 min. In group I, these changes were not significant during the period of observation. In group II, however, the percent decrement in CSF production was significant within 15 min after addition of bumetanide and progressively increased with time. The maximum decrease in CSF production was 47%.
Discussion
The results ofthe present study are the first in vivo demonstration of a significant decrease (-47%) of directly measured CSF production under strict standardized conditions in the presence ofan appropriate intracranial concentration ofbumetanide. These results, therefore, are consistent with NaCl cotransport carrier playing an important role in CSF production in a mammalian species.
Previous studies on mammalian CSF production in the presence of loop diuretics have revealed controversial results primarily because ofmethodological reasons as briefly stated in the Introduction and detailed elsewhere (5). Among the major issues discussed was the use of furosemide in most studies of CSF production (11) (12) (13) (14) (15) (16) (17) (18) . In addition to inhibiting NaCl cotransport, furosemide at concentrations of I0-3 mol/ liter, also inhibits CA (16) (Fig. 1) which, per se, may decrease CSF production (18) . Bumetanide is up to 40 times more potent in inhibiting NaCl cotransport and only seven times more potent in inhibiting CA than furosemide (16, 18) . Therefore, for inhibiting choroidal NaCl cotransport, bumetanide is superior to furosemide; yet systematic studies with bumetanide are lacking.
In two important negative studies (16, 18) , Vogh and associates used bumetanide in a limited number of rats and rabbits and concluded that bumetanide had no effect on CSF production. In experiments with nephrectomized rabbits (n = 3), bumetanide (50 mg/kg) was dissolved in ethanol and injected into the peritoneum (16) . Bumetanide is barely soluble in aqueous solutions and could have in part precipitated within the peritoneum, and, therefore, may not have been adequately (27) , showed that in anesthetized, mechanically ventilated dogs, bumetanide at a concentration of 10-5 mol/ liter decreased the flux of the radioactive Cl-from blood into CSF perfusate by about 50%. In the present study we directly measured canine CSF production, and bumetanide decreased CSF production by 47%, the same amount as radioactive chloride entry.
Most recently, in a number of important in vitro studies (28) (29) (30) using rat isolated CP, Johanson and colleagues showed that choroidal cellular uptake of radioactive K+ (86Rb as the marker), Na' and Cl-was diminished up to -45-50% by pretreatment with bumetanide ( l0-5 to 10-4 mol/liter), indicating the presence ofa bumetanide-inhibitable Na, K, 2C1 cotransporter. Johanson and colleagues (30) also showed up to 30% reduction of radioactive Cl-flux from blood to CSF in rats pretreated with ethacrynic acid (50 mg/kg intravenously), another loop diuretic.
The results of the present study do not allow us to localize the exact sites ofthe cotransporter. However, in vitro studies of Johanson et al. (28, 29) using rats, and of Saito and Wright (31 ) using bullfrogs localize the cotransporter in CP cells. Studies of Betz (32) suggest that the cotransporter may also exist in cerebral capillaries. It is noted that Saito and Wright (31 ) In summary, data obtained in the present study along with the radioactive ion flux studies in dogs (27) and both in vivo (30) and in vitro CP studies (28, 29) in rats strongly indicate the presence ofNaCl cotransport in mammalian CNS. Furthermore, the data from this study showing that bumetanide decreases CSF production, along with our previous data (33) (34) (35) showing that CSF ionic composition and CSF [Na'-Cl-] are not affected by bumetanide, indicate that NaCl cotransport is involved primarily in volume regulation of CSF. These findings are in contrast to ionic changes induced by loop diuretics in CP intracellular fluid (30) . Lack of effect of bumetanide on CSF acid-base regulation is important, since ionic composition ofcerebral fluids plays a major role in control ofbreathing and in neuronal activity.
It is to be hoped future research should result in isolation of the carrier and synthesis ofnew chemical compounds that preferentially decrease CSF production without having a major renal effect. Such compounds could be used to decrease cerebral edema which commonly accompanies various CNS pathological processes and impairs CNS functions.
